<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01032044</url>
  </required_header>
  <id_info>
    <org_study_id>MKT-2009-BE-01</org_study_id>
    <nct_id>NCT01032044</nct_id>
  </id_info>
  <brief_title>CLE for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia</brief_title>
  <acronym>CLEAN-MARGIN</acronym>
  <official_title>Confocal Laser Endomicroscopy for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mauna Kea Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cellvizio Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mauna Kea Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study focuses on demonstrating the value of probe-based Confocal Laser Endomicroscopy
      (pCLE) in guiding endoscopic therapeutic procedures in Barrett's Esophagus (BE).

      It is a randomized controlled outcomes study including patients already treated for Barrett's
      Esophagus lesion(s) and undergoing high definition white light endoscopy follow up procedure,
      with or without pCLE (2 arms will be considered in this study). The procedures will be
      carried out per standards of practice with appropriately trained physicians.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a randomized controlled outcomes study including patients already treated for Barrett's
      Esophagus lesion(s) and undergoing high definition white light endoscopy follow up procedure,
      with or without pCLE guided evaluation (2 arms will be considered in this study). The
      procedures will be carried out per standards of practice with appropriately trained
      physicians.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Barrett's Esophagus (BE) Participants With a Composite Outcome of &quot;Optimally Treated&quot;</measure>
    <time_frame>3 month follow-up endoscopic procedure</time_frame>
    <description>Number of Barrett's Esophagus (BE) Participants with a Composite Outcome of &quot;Optimally Treated&quot;, in each group defined as patients for whom all lesions are ablated when disease is present, or not ablated when disease is absent, or have complete ablation of all disease at the 3 month follow-up.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Barrett Syndrome</condition>
  <condition>Barrett's Syndrome</condition>
  <condition>Barrett's Esophagus</condition>
  <condition>Barrett Esophagus</condition>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Standard endoscopic evaluation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard high-definition white light endoscopy guided evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pCLE-guided evaluation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic evaluation of BE guided by probe-based Confocal Laser Endomicroscopy (pCLE guided evaluation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard endoscopic evaluation</intervention_name>
    <description>Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy</description>
    <arm_group_label>Standard endoscopic evaluation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>pCLE guided evaluation</intervention_name>
    <description>Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.</description>
    <arm_group_label>pCLE-guided evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with BE with Intestinal Metaplasia, Low Grade-IntraEpithelial Neoplasia/High
             Grade-IntraEpithelial Neoplasia as the original indication for ablative treatment.

          -  Undergoing any type of endoscopic BE ablation treatment

          -  &lt;2cm of circumferential BE and &lt;5 total islands of BE on prior to last ablation.

          -  Age &gt; 18 years

          -  Ability to provide written, informed consent

        Exclusion Criteria:

          -  Participation in another clinical study

          -  Circumferential BE

          -  Complete eradication of BE documented by biopsies

          -  Inability to obtain biopsies due to anticoagulation, varices, etc.

          -  Allergy to fluorescein

          -  Pregnancy

          -  Renal insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wallace, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic Jacksonville, Florida, United States</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Osdoit</last_name>
    <role>Study Director</role>
    <affiliation>Mauna Kea Technologies, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2009</study_first_submitted>
  <study_first_submitted_qc>December 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2009</study_first_posted>
  <results_first_submitted>November 3, 2015</results_first_submitted>
  <results_first_submitted_qc>March 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 22, 2016</results_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Barrett's esophagus</keyword>
  <keyword>EsoGastroDuodenoscopy</keyword>
  <keyword>Barrett's carcinoma</keyword>
  <keyword>adenocarcinoma</keyword>
  <keyword>Cellvizio</keyword>
  <keyword>endomicroscopy</keyword>
  <keyword>probe-based Confocal Laser Endomicroscopy</keyword>
  <keyword>pCLE</keyword>
  <keyword>Radio-frequency ablation</keyword>
  <keyword>Endoscopic mucosal resection</keyword>
  <keyword>Photodynamic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Treatment</title>
          <description>Standard high-definition white light endoscopy guided treatment
Standard endoscopic treatment of BE: Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy</description>
        </group>
        <group group_id="P2">
          <title>pCLE-guided Treatment</title>
          <description>Endoscopic treatment of BE guided by probe-based Confocal Laser Endomicroscopy
pCLE guided endoscopic treatment of BE: Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Procedure</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Exploratory analysis of the data according to the intent-to-treat principle resulted in no suggestion of systematic bias in the two groups regarding withdrawals. Only 1 patient was withdrawn because of intolerance to fluorescein.</population>
      <group_list>
        <group group_id="B1">
          <title>Standard Endoscopic Evaluation</title>
          <description>Standard high-definition white light endoscopy guided evaluation
Standard endoscopic evaluation: Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy</description>
        </group>
        <group group_id="B2">
          <title>pCLE-guided Evaluation</title>
          <description>Endoscopic evaluation of BE guided by probe-based Confocal Laser Endomicroscopy (pCLE guided evaluation)
pCLE guided evaluation: Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="164"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.9" lower_limit="45.4" upper_limit="87.2"/>
                    <measurement group_id="B2" value="69.6" lower_limit="50.2" upper_limit="86.1"/>
                    <measurement group_id="B3" value="68.8" lower_limit="45.4" upper_limit="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Barrett's Esophagus (BE) Participants With a Composite Outcome of &quot;Optimally Treated&quot;</title>
        <description>Number of Barrett's Esophagus (BE) Participants with a Composite Outcome of &quot;Optimally Treated&quot;, in each group defined as patients for whom all lesions are ablated when disease is present, or not ablated when disease is absent, or have complete ablation of all disease at the 3 month follow-up.</description>
        <time_frame>3 month follow-up endoscopic procedure</time_frame>
        <population>Among the 141 patients who completed the initial procedure, 119 had follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Endoscopic Evaluation</title>
            <description>Standard high-definition white light endoscopy guided evaluation
Standard endoscopic evaluation: Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy</description>
          </group>
          <group group_id="O2">
            <title>pCLE-guided Evaluation</title>
            <description>Endoscopic evaluation of BE guided by probe-based Confocal Laser Endomicroscopy (pCLE guided evaluation)
pCLE guided evaluation: Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Barrett's Esophagus (BE) Participants With a Composite Outcome of &quot;Optimally Treated&quot;</title>
          <description>Number of Barrett's Esophagus (BE) Participants with a Composite Outcome of &quot;Optimally Treated&quot;, in each group defined as patients for whom all lesions are ablated when disease is present, or not ablated when disease is absent, or have complete ablation of all disease at the 3 month follow-up.</description>
          <population>Among the 141 patients who completed the initial procedure, 119 had follow-up visits.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from inclusion to 3 months follow-up visit post-procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Treatment</title>
          <description>Standard high-definition white light endoscopy guided treatment
Standard endoscopic treatment of BE: Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy</description>
        </group>
        <group group_id="E2">
          <title>pCLE-guided Treatment</title>
          <description>Endoscopic treatment of BE guided by probe-based Confocal Laser Endomicroscopy
pCLE guided endoscopic treatment of BE: Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Intolerance to Fluorescein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Michael B. Wallace</name_or_title>
      <organization>Mayo Clinic, Jacksonville, Florida, USA</organization>
      <phone>904 953-7630</phone>
      <email>wallace.michael@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

